Advertisement

Fulminant Type 1 Diabetes in Japan

Chapter

Abstract

Fulminant type 1 diabetes is a novel subtype within type 1 diabetes ­characterized by a remarkably abrupt onset, absence of islet-related autoantibodies, and almost no C-peptide secretion even at the onset of the disease. Several lines of evidence suggest that viral infection contributes to the development of fulminant type 1 diabetes: (1) preceding influenza-like symptoms, (2) elevated IgA level to the enterovirus common antigen, (3) association of HLA-B*4002, (4) several patients with an elevation of antiviral antibodies, (5) TLR expression in the pancreas of patients, and (6) detection of enterovirus or cytomegalovirus in the pancreas of patients.

Keywords

Beta Cell Beta Cell Destruction Beta Cell Death Paired Seron Fulminant Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This study was supported in part by a Grant-in Aid from the Japanese Society for the Promotion of Science (Kakenhi), a grant from a Health and Labour Sciences Research Grant on Research on Intractable Diseases from the Japanese Ministry of Health, Labour and Welfare, a grant from the Japan Medical Association and continuous support of the Japan Diabetes Society.

References

  1. Aida K, Nishida Y, Tanaka S, Maruyama T, Shimada A, Awata T, Suzuki M, Shimura H, Takizawa S, Ichijo M, Akiyama D, Furuya F, Kawaguchi A, Kaneshige M, Itakura J, Fujii H, Endo T, Kobayashi T (2011) RIG-I- and MDA5-initiated innate immunity linked with adaptive immunity accelerates beta-cell death in fulminant type 1 diabetes. Diabetes 60:884–889PubMedCrossRefGoogle Scholar
  2. Akatsuka H, Yano Y, Gabazza EC, Morser J, Sasaki R, Suzuki T, Fujiwara R, Katsuki A, Takei Y, Sumida Y (2009) A case of fulminant type 1 diabetes with coxsackie B4 virus infection diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract 84:e50–e52PubMedCrossRefGoogle Scholar
  3. Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS (2006) Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 54(Suppl 2):S14–S17PubMedCrossRefGoogle Scholar
  4. Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, Lee HK, Park KS (2007) Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia 50:2276–2279PubMedCrossRefGoogle Scholar
  5. Goto A, Takahashi Y, Kishimoto M, Nakajima Y, Nakanishi K, Kajio H, Noda M (2008) A case of fulminant type 1 diabetes associated with significant elevation of mumps titers. Endocr J 55:561–564PubMedCrossRefGoogle Scholar
  6. Hanafusa T, Imagawa A (2007) Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3:36–45PubMedCrossRefGoogle Scholar
  7. Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H (2005) Report of Japan Diabetes Society Committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Japan Diab Soc 48(Suppl 1):A1–A13 (in Japanese)Google Scholar
  8. Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H (2008) Report of the Japan Diabetes Society’s Committee on research on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Japan Diab Soc 51:531–536 (in Japanese)Google Scholar
  9. Haseda F, Imagawa A, Murase-Mishiba Y, Sano H, Hirano-Kuwata S, Ueda H, Terasaki J, Hanafusa T (2011) Low CTLA-4 expression in CD4(+) helper T-cells in patients with fulminant type 1 diabetes. Immunol Lett 139:80–86PubMedCrossRefGoogle Scholar
  10. Hwang YC, Jeong IK, Chon S, Oh S, Ahn KJ, Chung HY, Woo JT, Kim SW, Kim JW, Kim YS (2010) Fulminant type 1 diabetes mellitus associated with acute hepatitis A. Diabet Med 27:366–367PubMedCrossRefGoogle Scholar
  11. Hyöty H, Taylor KW (2002) The role of viruses in human diabetes. Diabetologia 45:1353–1361PubMedCrossRefGoogle Scholar
  12. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y, Osaka IDDM Study Group (2000a) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301–307PubMedCrossRefGoogle Scholar
  13. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000b) A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence. Ann Med 32:539–543PubMedCrossRefGoogle Scholar
  14. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352PubMedCrossRefGoogle Scholar
  15. Imagawa A, Hanafusa T, Makino H, Miyagawa JI, Juto P (2005a) High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48:290–293PubMedCrossRefGoogle Scholar
  16. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H (2005b) Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48:294–300 [Erratum in: Diabetologia. 2008;51:524–526]PubMedCrossRefGoogle Scholar
  17. Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H (2008) Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Res Clin Pract 82:233–237PubMedCrossRefGoogle Scholar
  18. Jun HS, Yoon JW (2001) The role of viruses in type I diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 44:271–285PubMedCrossRefGoogle Scholar
  19. Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H, Committee on Type 1 Diabetes, Japan Diabetes Society (2009) Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 52:2513–2521PubMedCrossRefGoogle Scholar
  20. Kawasaki E, Imagawa A, Makino H, Uga M, Abiru N, Hanafusa T, Uchigata Y, Eguchi K (2008) Differences in the contribution of the CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Diabetes Care 31:1608–1610PubMedCrossRefGoogle Scholar
  21. Kim NH, Kim HY, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS, Kim SG (2009) A pooled analysis of 29 patients with fulminant type 1 diabetes in Korea: a comparison with a nationwide survey in Japan. Diabetes Res Clin Pract 86:e43–e45PubMedCrossRefGoogle Scholar
  22. Moreau C, Drui D, Arnault-Ouary G, Charbonnel B, Chaillous L, Cariou B (2008) Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab 34:529–532PubMedCrossRefGoogle Scholar
  23. Murase Y, Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H (2007) Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy–a nationwide 5-year-study in Japan. Diabetologia 50:531–537PubMedCrossRefGoogle Scholar
  24. Sano H, Terasaki J, Tsutsumi C, Imagawa A, Hanafusa T (2008) A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 79:e8–e9PubMedCrossRefGoogle Scholar
  25. Sano H, Terasaki J, Mishiba Y, Imagawa A, Hanafusa T (2011) Exenatide, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic beta-cell destruction induced by encephalomyocarditis virus. Biochem Biophys Res Commun 404:756–761PubMedCrossRefGoogle Scholar
  26. Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, Sato H, Fujita T, Kaneko T, Asano Y, Kikuchi K (2001) Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. J Am Med Assoc 285:1153–1154CrossRefGoogle Scholar
  27. Shibasaki S, Imagawa A, Tauriainen S, Iino M, Oikarinen M, Abiru H, Tamaki K, Seino H, Nishi K, Takase I, Okada Y, Uno S, Murase-Mishiba Y, Terasaki J, Makino H, Shimomura I, Hyoty H, Hanafusa T (2010) Expression of toll-like receptors in the pancreas of recent-onset fulminant type 1 diabetes. Endocr J 57:211–219PubMedCrossRefGoogle Scholar
  28. Shimada A, Maruyama T (2004) Encephalomyocarditis-virus-induced diabetes model resembles “fulminant” type 1 diabetes in humans. Diabetologia 47:1854–1855PubMedCrossRefGoogle Scholar
  29. Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T (2006) Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab 91:471–476PubMedCrossRefGoogle Scholar
  30. Takaike H, Uchigata Y, Iwamoto Y, Imagawa A, Iwahashi H, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Hanafusa T, Makino H (2008) Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med 40:395–400PubMedCrossRefGoogle Scholar
  31. Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanfusa T (2009) The Research Committee of type 1 diabetes in the Japan diabetes. Class II HLA genotype in fulminant type 1 diabetes. Diabetes 58(Suppl 1):A299Google Scholar
  32. Zheng C, Zhou Z, Zang C, Lin J, Yang L, Wang J, Zhou W, Yang Y, Che Z (2009) Prevalence, clinical and immunological features of fulminant type 1 diabetes among Chinese Hunan Han population. J Japan Diab Soc 51(Suppl 1):S–188Google Scholar
  33. Zheng C, Zhou Z, Yang L, Lin J, Huang G, Li X, Zhou W, Wang X, Liu Z (2011) Fulminant type 1 diabetes mellitus exhibits distinct clinical and autoimmunity features from classical type 1 diabetes mellitus in Chinese. Diabetes Metab Res Rev 27:70–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Metabolic Medicine, Graduate School of MedicineOsaka UniversitySuitaJapan
  2. 2.Department of Internal Medicine (I)Osaka Medical CollegeTakatsukiJapan

Personalised recommendations